Response:Intrathecal methotrexate and central nervous system events

Abstract

Whether intrathecal methotrexate (MTX) should be administered to diffuse large B-cell lymphoma (DLBCL) patients to prevent central nervous system (CNS) relapse is highly controversial. In a recent issue of Blood, Boehme et al provided further evidence for the inefficacy of this prophylactic procedure. 1 They should be congratulated for this information that is very useful for our daily practice and for patients. One could argue that CNS relapse was not the primary end point of the RICOVER study and that the retrospective analysis was possible because of protocol violations resulting in 42.9% of patients with bone marrow or upper neck involvement not receiving the intrathecal MTX planned in the study design. However, the data are strong and similar to the recent analysis of 899 patients included in the Southwest Oncology Group studies. 2 First, the authors confirmed that CNS relapse in DLBCL patients is a rare event (Ͻ 5%) in the rituximab era, a "low" rate that could be considered as an intrinsic limitation of any prophylactic treatment. Second, they also confirmed that a high proportion of CNS relapses are observed concurrently with systemic relapses or refractory diseases and, thus, reflect failure to control systemic disease rather than the consequences of disease's sanctuary for which a prophylactic measure should be taken. In this regard, it would be interesting to know the number of isolated CNS relapses developing in patients in CR treated or not with intrathecal MTX. Third, and most importantly, intrathecal MTX had no effect on the low rate of CNS relapses observed in DLBCL patients with BM or upper neck involvement treated with R-CHOP14. Whether intrathecal MTX should be administered to patients at high risk to develop CNS relapses (elevated lactate dehydrogenase, poor performance status, and Ͼ1 extranodal site) was not answered in this study. But the rate of 43% of CNS relapses that was observed in this population despite intrathecal prophylaxis, in line with previous retrospective analysis, 3 is very disappointing.Another matter of debate is whether intrathecal MTX is associated with short-and long-term toxicity. The interest of this question could appear to be modest in the field of DLBCL, where this procedure must be abandoned. However, the question is pertinent in other settings where intrathecal prophylaxis has been proven to be beneficial (eg, Burkitt lymphoma, acute lymphoblastic leukemia). The RICOVER trial offers a unique opportunity to address this issue. What is the rate of myelotoxicity, neurotoxicity, renal failure, and mucositis in patients receiving or not intrathecal MTX? Our daily practice suggests that intrathecal MTX may add toxicity to standard polychemotherapy regimen, and, indeed, this was recently shown in 352 children with anaplastic large-cell lymphoma, where 6 cycles of MTX 1 g/m 2 plus intrathecal MTX were significantly more toxic (myelotoxicity, infections, stomatitis) that 6 cycles of MTX 3 g/m 2 . 4 If the toxicity for patients having received intrathecal MTX in the RICOVE...

Multiple secondary cauda equina non-Hodgkin’s lymphoma: a case report and literature review

“…A previous database study of 605 newly diagnosed DLBCL patients who had not undergone CNS prophylaxis showed that the probability of secondary CNS involvement at 1 year after diagnosis was 4.5% [14]. The prognosis of patients experiencing secondary CNS involvement, especially during progression or after relapse of systemic lymphoma is extremely poor [14, 15]. Spinal cord, especially cauda equina lymphoma is rarely reported.…”

Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

“…Some reports have suggested that a high-dose intravenous rituximab infusion or intrathecal rituximab infusion may be an effective treatment option [13], although the clinical safety of such treatments has not been yet been confirmed. In order to prevent CNS recurrence of DLBCL, intrathecal chemotherapy such as MTX and cytarabine is currently performed in many institutions, although its efficacy has been controversial [2,[14][15][16][17][18]. Kim et al described the treatment of 73 DLBCL patients with secondary CNS involvement in 11 institutions in Korea [14].…”

ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients

“…Given the serious toxicities (leukopenia, infections, mucositis) related to i.t. injections of cytotoxic drugs [30,31], this practice should be restricted to very high-risk patients or abandoned altogether. The only exception may be for patients with involvement of the testes where i.t.…”